Anti-TNF Drugs for Rheumatic Disease had Sales of Over USD 30 Bn in 2015, States Kuick Research in New Report Published at MarketPublishers.com
16 Nov 2016 • by Natalie Aster
LONDON – Currently, the anti-TFN drugs are in the top ten blockbuster drugs globally. They have been residing upon the word’s pharma landscape for a long time. As of 2015, the anti-TNF drugs (namely, Remicade & Enbrel, Humira) for the rheumatic disease had totaled sales of over USD 30 billion.
At present, there are more than two dozen tumor necrosis factor inhibitors that are commercially available in the marketplace. Besides, over 150 tumor necrosis factor inhibitors in the clinical pipeline.
The three pharma agents directed against TNF-alpha have been extensively used for management of ankylosing spondylitis, rheumatoid arthritis, etc. The two novel agents used for treatment of such diseases as rheumatoid arthritis and Crohn’s disease to the marketplace has recently took place.
The usage of TNF-antagonists has demonstrated good results and cleared the way for the further research in this field.
New research report “Tumor Necrosis Factor Inhibiotrs Market & Clinical Pipeline Outlook 2022” worked out by Kuick Research offers a comprehensive guide to the global market for tumor necrosis factor inhibitors. The study comprises an all-round overview of these inhibitors.
It throws light on approaches used in the development of anti-TNF. The report covers usage of TNF (and sometimes its receptor) in the management of different diseases and disorders.
The research study focuses on blockbuster drugs from this market space. It proceeds with a discussion of the market dynamics. The research report limelights future implications of this marketplace.
The study comprises clinical insights into marketed inhibitors. It also looks at the inhibitors suspended in the clinical pipeline. Top companies like UCB, LEO Pharma, Ablynx, Celltrion, and more are available in the report, too. Future outlook up to 2022 can be found in the research study.
More new reports by Kuick Research can be found at its page.